1 / 31

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

This overview explores the burden, prevalence, and incidence rates of TD, its impact on QoL, risk factors, and differential diagnosis with tardive dyskinesia or drug-induced parkinsonism. Learn about screening, prevention, treatment with VMAT2 inhibitors, and real-world evaluation study results. The patient's perspective and AAN recommendations are also discussed.

ccorey
Download Presentation

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

  2. Overview of TD

  3. TD Burden, Prevalence, Incidence

  4. TD Prevalence and Incidence Rates

  5. TD Burden and Impact on QoL

  6. Impact of TD on Highly Functional Patients

  7. TD Risk Factors

  8. Differential Diagnosis

  9. Is It Tardive Dyskinesia or Drug-Induced Parkinsonism?

  10. Schooler-Kane CriteriaCommonly Used Criteria Based on AIMS Score

  11. AIMSUseful for Screening and Following Symptoms

  12. AIMSUseful for Screening and Following Symptoms (cont)

  13. Interprofessional Team Approach

  14. TD Prevention and Treatment

  15. VMAT2 Inhibitors

  16. ARM-TD and AIM-TDStudy Designs

  17. ARM-TD and AIM-TDResults

  18. RIM-TD

  19. KINECT 3 and KINECT 4Study Designs

  20. KINECT 3 and KINECT 4Results

  21. Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents (RE-KINECT)

  22. VMAT2 Inhibitors and Psychiatric AEs

  23. Comparison of Deutetrabenazine and Valbenazine

  24. Comparison of Deutetrabenazine and Valbenazine (cont)

  25. Considerations for Initiating TreatmentThe Patient's Perspective

  26. AAN Recommendations for Treatment of TD

  27. Concluding Remarks

  28. Concluding Remarks (cont)

  29. Abbreviations

  30. Abbreviations (cont)

More Related